Multiple Programs Advancing to IND and the Clinic
We are advancing several programs for the treatment of viral infectious diseases such as HIV, herpes simplex viruses (HSV 1&2), and Hepatitis B.
View Our PipelineLeveraging Breakthroughs in CRISPR Gene Editing Technology
Excision BioTherapeutics’ dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction and resulting in a potentially curative approach. We are advancing the first and only technology in history to remove human immunodeficiency virus (HIV) genomes from animals and generate curative treatments for HIV1. We have established proof-of-concept in animals for HSV keratitis and Hepatitis B and are now poised to move these two programs toward the clinic.
1 Dash et al, Nat Comm 2019
A Proprietary Dual Cut Approach that Differentiates from Other CRISPR Approaches
Standard Gene Editing Approach
Single base cuts lead to viral escape
Excision’s CRISPR Approach
Excising large sections of viral DNA eliminates viral escape. The result is potentially curative.
Targeting Viral DNA with a Novel Platform Approach
Our platform enables in silico design of probes to analyze on- and off-target effects and integrates computational methods to design the most effective guide RNAs. By optimizing on-target sequence design and minimizing off-target binding, we can maximize efficacy and minimize side effects. We are transforming drug discovery and target validation from traditional to digital.
Evolution of Excision’s CRISPR Platform for Viral Elimination
